Kivu Bioscience president and COO Mohit Trikha (L) and Novo Holdings partner, venture investments Daniel O’Connell
October 28, 2024 08:00 AM EDTUpdated 09:47 AM
Financing
Startups

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

Kyle LaHucik

Senior Reporter

The Dutch biotech Synaf­fix has long been one of the top part­ners for bio­phar­ma com­pa­nies work­ing in an­ti­body-drug con­ju­gates. Now the com­pa­ny is spin­ning out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times